Evidence map›Paper›PMID 37900840›Full record

ArticleCase reports in oncology

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with

Ahmed Badran, Clara Steele, Hisham Alquaydheb, Ahmed Ba Theeb, Abdulmalik Bawazir, Mahmoud A Elshenawy, Jean Paul Atallah

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Ahmed BadranDepartment of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Clara SteeleSchool of Medicine, Brookfield Health Sciences Complex, University College Cork, Cork, Ireland.
Hisham AlquaydhebDepartment of Internal Medicine, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Ahmed Ba TheebFaculty of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Abdulmalik BawazirFaculty of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Mahmoud A ElshenawyDepartment of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Jean Paul AtallahDepartment of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Alfaisal University · SAKing Faisal Specialist Hospital & Research Centre · SAMenoufia University · EGPrince Sattam Bin Abdulaziz University · SAUniversity College Cork · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.

Indexed as

Anaplastic lymphoma kinase mutationCrizotinibSclerosing epithelioid fibrosarcoma

Identifiers

PMID37900840
PMCPMC10601707
OpenAlexW4386604896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.